{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052094","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.869436+00:00","generated_at":"2026-06-03T00:26:20.863293+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences Q1 revenue $19.3M (+2% YoY); wins $34M jury verdict against Alcon","bullets":["Q1 2024 revenue $19.3M (+2% YoY); Surgical Glaucoma $18.3M (+5%), Dry Eye $1.0M (-32%).","Net loss $16.3M ($0.33/share) vs $17.1M ($0.35/share); gross margin 86% vs 84% prior year.","Jury found willful infringement by Alcon; awards $5.5M lost profits + $28.5M royalty for Hydrus Microstent.","Reaffirms FY2024 revenue guidance $81M-$85M (0-5% growth) and adjusted op ex $107M-$110M.","Cash burn reduced to $10.8M (incl. $3.2M debt restructuring costs) from $17.7M in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052094","json":"https://secwatch.observer/filing/0000950170-24-052094.json","markdown":"https://secwatch.observer/filing/0000950170-24-052094.md","text":"https://secwatch.observer/filing/0000950170-24-052094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/0000950170-24-052094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/sght-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:26:20.863293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e948c3d9dabc5f0b70ab4a38c5c4e1361210f1e0","claim":"Sight Sciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $19.3 million. Guidance reaffirmed.","evidence_excerpt":"quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year. • Achieved total gross margin of 86% in the first quarter of 2024 compared to 84% in the same period in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000095017024052094/0000950170-24-052094-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$19.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}